Open AccessClinical characteristics and laboratory analyses of acute myeloid leukemia with t(16;21)(p11;q22)
Author(s) -
Zhifen Zhang,
Jianwen Zou,
Yuantang Li,
Zhanfeng Liu,
Rui Xu,
Wenjun Tian,
Zongchen Zhao,
Hui Sun,
Jingying Han,
Jia Wang,
Bingchang Zhang,
Ying Ju
Publication year - 2015
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2015.3051
Subject(s) - cytogenetics , myeloid leukemia , myeloid , molecular medicine , chromosomal translocation , medicine , oncology , transplantation , leukemia , oncogene , chromosomal abnormality , biology , cancer , immunology , karyotype , cell cycle , chromosome , genetics , gene
The present study reviewed three patients with acute myeloid leukemia (AML) who had the specific genetic abnormality t(16;21)(p11;q22). To investigate the clinical and laboratory characteristics of AML with t(16;21)(p11;q22) translocation, the similarities and differences of clinical characteristics and laboratory examinations were compared, and a literature review was conducted. According to the French-American-British classification system, patient 1 was M4, patient 2 was M1 and patient 3 was M2. The cytogenetic aberrations were 46, XY, t(16;21)(p11;q22)/47, idem, +21 for patient 1 and 46, XX, t(16;21)(p11;q22) for patients 2 and 3. Cytophagocytosis and cluster of differentiation 56 antigen expression were found in all three cases. The prognosis was poor in all the cases. AML with t(16;21)(p11;q22) is a specific subtype of AML that exhibits unique characteristics of morphology, immunology, cytogenetics and clinical features, as well as a poor prognosis. Stem cell transplantation may be the first and only choice for treatment.